Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
354 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (3)

Medical Condition

  • Show all (37)
  • Autoimmune Disorders (1)
  • Blood Disorders (1)
  • Bone & Muscle (1)
  • Cancer (10)
    • Breast Cancer (1)
    • (-) Gastrointestinal (1)
    • Lymphoma (1)
    • Multiple Myeloma (1)
    • (-) Sarcoma (2)
  • Diabetes (3)
  • Ear, Nose and Throat (1)
  • Healthy Volunteers (1)
  • Heart Disease (6)
  • Kidney Disease (1)
  • Neurological Disorders (7)
  • Pediatrics (2)
  • Surgery (1)
  • Vascular Conditions (2)
Displaying 1 - 3 of 3

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Condition: Cancer / Gastrointestinal
Investigator: Rachael Safyan, MD
Status: Closed
This study is being done to answer the following question: Does duloxetine (either 30 mg or 60 mg) prevent numbness, tingling, and/or pain caused by your colorectal cancer treatment with oxaliplatin? We are doing this study because we want to find out if duloxetine can prevent Oxaliplatin-Induced Peripheral Neuropathy (OIPN).
Read More

A Study for Patients with Malignant Peripheral Nerve Sheath Tumors Using Study Drugs PLX3397 and Sirolimus

Condition: Cancer / Sarcoma
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to determine if treatment with PLX3397 and Sirolimus will be tolerated and result in shrinking of the cancer or stopping the cancer from growing. In the phase I portion, the maximum tolerated dose of the study drug will be determined. In the phase II portion, progression-free survival will be assessed at the dose level found in…
Read More

Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to evaluate the safety and effectiveness of a new combination treatment involving two drugs: selinexor and ixazomib, for the treatment of dedifferentiated liposarcoma, malignant peripheral nerve sheath tumor, alveolar soft part sarcoma and Ewing sarcoma. The primary objective of the study is to…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science